Novo Settles Drug Marketing Claims For $26.7M

Law360, New York (June 10, 2011, 3:36 PM EDT) -- Novo Nordisk Inc. announced Friday that it would pay $26.7 million to resolve federal investigations and False Claims Act lawsuits in New York and Maryland brought by former employees and a physician over the marketing of its drugs for bleeding disorders and diabetes.

The drugmaker said it had reached a $25 million settlement with the U.S. Department of Justice and two individuals over the marketing of NovoSeven, which is approved for the treatment of bleeding disorders. The company faced allegations that it had improperly promoted the...
To view the full article, register now.